Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)

27 de agosto de 2026 atualizado por: Wan-Chuan Tsai, Far Eastern Memorial Hospital

Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients

Patients with end-stage kidney disease (ESKD) rely on maintenance hemodialysis. While high-flux hemodialysis improves small solute clearance, its removal of middle-molecule uremic toxins (e.g., α1-microglobulin [α1-MG]) remains insufficient, contributing to symptoms such as restless legs syndrome (RLS), pruritus, and poor sleep quality, which are also linked to increased cardiovascular risk. In this study, the investigators evaluate whether using a "Super High-Flux" dialyzer (a Type V high-performance dialyzer) during hemodialysis can safely improve the removal of middle-molecule uremic toxins-specifically α1-microglobulin (α1-MG)-and relieve RLS symptoms in maintenance hemodialysis patients.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.

In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.

It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.

This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Wan-Chuan Tsai, M.D., Ph.D.
  • Número de telefone: 1780 886-289667000
  • E-mail: mkks618@gmail.com

Locais de estudo

    • Banciao Dist.
      • New Taipei City, Banciao Dist., Taiwan, 220
        • Far Eastern Memorial Hospital
        • Contato:
          • Wan-Chuan Tsai, M.D., Ph.D.
          • Número de telefone: 1780 886-277281780
          • E-mail: mkks618@gmail.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  1. Diagnosis of Restless Legs Syndrome according to standard criteria.
  2. Age ≥ 20 years.
  3. Maintenance high-flux hemodialysis for ≥ 3 months.
  4. Stable vascular access (AV fistula or AV graft).
  5. Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
  6. Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
  7. Clinically stable condition for the past 4 weeks.
  8. Able and willing to comply with study protocol

Exclusion Criteria:

  1. Low-flux HD or temporary catheter use
  2. Serum albumin < 2.5 g/dL
  3. Recent hospitalization (within 4 weeks)
  4. Scheduled kidney transplantation
  5. Active malignancy or infection
  6. Pregnancy
  7. Any condition impairing protocol adherence

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
Sem intervenção: High-Flux HD
Receives 12 weeks of High-Flux HD as usual care

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit. The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in International Restless Legs Scale (IRLS) Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity). Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum Albumin Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses sleep quality. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in 5-D Itch Scale Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses pruritus severity. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses quality of life. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Kappa Free Light Chains Reduction ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Lambda Free Light Chains Reduction ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

30 de setembro de 2027

Conclusão do estudo (Estimado)

30 de setembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

27 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de agosto de 2026

Primeira postagem (Real)

31 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

31 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • FEMH-IRB-TSAI2025
  • FEMH-IIT-2026-01 (Número de outro subsídio/financiamento: Far Eastern Memorial Hospital)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Individual-level deidentified participant data will be made available by the corresponding author of the paper upon request by email. The data will be available for 3 years after formal publication.

Prazo de Compartilhamento de IPD

The data will become available after completing the study for 1 year and for 3 years after formal publication.

Critérios de acesso de compartilhamento IPD

Data will be made available by the corresponding author of the paper upon request by email.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .